Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

from http://www.alnylam.com/our-approach/about-alnylam/

Research Grants 8 show all


$590K
2006

$7.5M
2008

$1.2M
2009

$16.5M
2013

$16M
2017

Publications 257 show all

  • 22
    RNA, Small Interfering/chemistry
  • 20
    RNA Interference
  • 20
    RNA, Small Interfering/genetics
  • 14
    RNA, Small Interfering/administration & dosage
  • 12
    RNA, Small Interfering/therapeutic use
  • 10
    Gene Silencing
  • 9
    Acetylgalactosamine/chemistry
  • 9
    Liver/metabolism
  • 7
    RNAi Therapeutics
  • 5
    Hepatocytes/metabolism

Patents 2,122show all

  • 872
    C12N - Microorganisms or enzymes
  • 524
    A61K - Preparations for medical, dental, or toilet purposes
  • 155
    C07H - Sugars
  • 88
    Y02A - Technologies for adaptation to climate change
  • 66
    C12Y - Enzymes
  • 56
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 52
    C07K - Peptides
  • 46
    C07C - Acyclic or carbocyclic compounds
  • 32
    A61M - Devices for introducing media into, or onto, the body
  • 24
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Clinical Trials 163show all

83Phase 332Phase 215Phase 113Phase 1/Phase 212N/A

SEC Filings show all


204
8-K

47
10-Q

16
10-K

1
D

1
S-1

Contact Information

300 Third Street 3rd Floor
Cambridge, MA 02142
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$1,534,600,000251-5002019-04-08Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-04-08$800,000,000Post Ipo EquityRegeneron Pharmaceuticals
2003-07-07$24,600,000Series UnknownAtlas Venture, Merck, Cardinal Partners, Abingworth, ARCH Venture Partners
2014-01-13$700,000,000Post Ipo EquityGenzyme
2011-03-28$10,000,000Post Ipo EquityTakeda Pharmaceutical

SEC Form D Funding Events

DateOfferedSoldType
2005-01-18Unknown Unknown Other (Paper Filing)